Thursday, September 24, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 25, 2025

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

View original at globenewswire.com
PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff Dublin, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • PD-1 resistance in head and neck cancer arises from complex immune evasion mechanisms, including low tumor immunogenicity, impaired T-cell infiltration, and the presence of immunosuppressive microenvironments

    80% confidence

  • The Immune Checkpoint Inhibitors segment is expected to reach US$1 Billion by 2030 with a CAGR of 8.9%

    80% confidence

  • The Asia-Pacific region is expanding its research footprint, especially in countries with high incidence of head and neck cancers linked to tobacco and HPV

    80% confidence

  • Growth in the PD-1 resistant head and neck cancer market is driven by factors such as expanding clinical recognition of immunotherapy resistance, rising incidence of advanced-stage HNSCC, and strong research momentum around next-generation immune interventions

    80% confidence

  • The limited durability of response in monotherapy PD-1 regimens is prompting accelerated development of combination therapies targeting multiple immune checkpoints and tumor pathways

    80% confidence

  • China is forecasted to grow at an impressive 13.1% CAGR to reach $222.4 Million by 2030

    80% confidence

  • Availability of genomic and immunological profiling tools is improving patient selection, while regulatory support for breakthrough designations is facilitating trial progression

    80% confidence

  • Tumors with low PD-L1 expression, defective antigen presentation, or enriched T-regulatory cells often fail to respond to checkpoint blockade

    80% confidence

  • The global market for PD-1 Resistant Head and Neck Cancer was valued at US$1.6 Billion in 2024 and is projected to reach US$3 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030

    80% confidence

  • The Cytotoxic Agents segment is set to grow at 10.3% CAGR over the analysis period

    80% confidence

  • North America and Europe are leading in clinical research and treatment innovation for PD-1 resistant head and neck cancer

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff — Source | Via News | Via News